Endocrine Abstracts

Objective: Despite being the most common endocrine malignancy, the management of thyroid cancer in the UK remains sub-optimal, with reduced survival rates compared with Western Europe. The British Thyroid association published national guidelines in March 2002 to help standardize and improve the management and survival of thyroid cancer in the UK. We have audited the management of thyroid cancer in a large district hospital comparing the results to the standards set by the Bri...

Objective: Despite being the most common endocrine malignancy, the management of thyroid cancer in the UK remains sub-optimal, with reduced survival rates compared with Western Europe. The British Thyroid association published national guidelines in March 2002 to help standardize and improve the management and survival of thyroid cancer in the UK. We have audited the management of thyroid cancer in a large district hospital comparing the results to the standards set by the Bri...

Background: The use of peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NETs) is increasing, but PRRT remains palliative at this time. Estrogen (E2) has been extensively linked to cellular proliferation and DNA repair in other cancers. Our aim is to determine whether NET cells are similarly affected by estrogen and whether inhibition of estrogen receptor alpha (ESR1) increases radiosensitivity of NET cells, which could improve PRRT response.<p class=...

Bone loss in anorexia nervosa and following bariatric surgery is associated with an elevated circulating concentration of the gastrointestinal anorexigenic hormone peptide YY (PYY), which acts principally via the Y1R and Y2R receptors. Selective deletion of Y1R in osteoblasts or Y2R in the hypothalamus results in high bone mass, but deletion of PYY has resulted in conflicting skeletal phenotypes leading to uncertainty regarding its role in the regulation of bone mass. We hypot...

Primary Aldosteronism (PA) is the most frequent cause of endocrine hypertension. Three forms of familial hyperaldosteronism (FH) have been described, named FH-I to -III. Recently, a mutation of KCNJ5 has been shown to be associated with FH-III, whereas the cause of FH-II is still unknown. In this study we searched for mutations in KCNJ5 in 46 patients from 21 families with FH, in which FH-I was excluded. We identified a new germline G151E mutation in two PA affected subjects f...